Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of November 2015. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report primarily serves to incorporate by reference a press release issued on November 20, 2015, and documents related to a Special Shareholders' Meeting scheduled for December 22, 2015.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose corporate events and does not contain a financial statement or earnings report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this text. The filing focuses on corporate governance activities, specifically the notification of a Special Shareholders' Meeting and the distribution of proxy materials.
Guidance, Outlook, and Corporate Events
- Press Release: A press release dated November 20, 2015, is attached as Exhibit 99.1 and incorporated by reference, though its specific content is not detailed in the filing text.
- Shareholder Meeting: An invitation to a Special Shareholders' Meeting is scheduled for December 22, 2015 (Exhibit 99.3).
- Voting Materials: The filing includes a proxy form (Exhibit 99.4) and a report on shares and voting rights (Exhibit 99.5).
Investor Verification Checklist
- Verify the specific content of the November 20, 2015 press release (Exhibit 99.1) to understand the business context triggering this filing.
- Review the agenda for the Special Shareholders' Meeting on December 22, 2015, to identify proposed corporate actions.
- Confirm the registrant's name is Galapagos NV, as the metadata reference to "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing header.
- Check subsequent filings for financial data, as this 6-K does not contain quantitative financial metrics.